The cholesterol-lowering therapy evolocumab reduced the risk of serious adverse cardiac events by nearly one-third in patients with diabetes and no known significant atherosclerosis, according to...
Embargoed until 1 p.m. CT/2 p.m. ET, Friday, March 13, 2026 WASHINGTON and DALLAS, March 13, 2026 — The American College of Cardiology (ACC), the American Heart Association...
Fish oil supplements are touted for many benefits, including improving heart, brain, eye, joint, and skin health. Despite these potential benefits, there have been concerns about...
In a recent study published in Lancet Diabetes and Endocrinology, a large collaborative team of researchers investigated the increased risk of diabetes with statin use, including...
Dr. Steve Nissen SAN DIEGO, Calif. – A new analysis of a large trial of a novel lipid-lowering agent shows a particularly significant reduction in cardiovascular...
A region-wide study of more than 50,000 patients with atrial fibrillation found that those who started statin therapy within 1 year of diagnosis had a higher...
Recent Comments